Journal articles: 'Supportive medicines in cancer'

1

Gurney, Jason K., James Stanley, Jonathan Adler, Heather McLeod, June Atkinson, and Diana Sarfati. "National Study of Pain Medicine Access Among Māori and Non-Māori Patients With Lung Cancer in New Zealand." JCO Global Oncology, no. 7 (August 2021): 1276–85. http://dx.doi.org/10.1200/go.21.00141.

Full text

Abstract:

PURPOSE Pain is among the most common and consequential symptoms of cancer, particularly in the context of lung cancer. Māori have extremely high rates of lung cancer, and there is evidence that Māori patients with lung cancer are less likely to receive curative treatment and more likely to receive palliative treatment and to wait longer for their treatment than non-Māori New Zealanders. The extent to which Māori patients with lung cancer are also less likely to have access to pain medicines as part of their supportive care remains unclear. METHODS Using national-level Cancer Registry and linked health records, we describe access to subsidized pain medicines among patients with lung cancer diagnosed over the decade spanning 2007-2016 and compare access between Māori and non-Māori patients. Descriptive and logistic regression methods were used to compare access between ethnic groups. RESULTS We observed that the majority of patients with lung cancer are accessing some form of pain medicine and there do not appear to be strong differences between Māori and non-Māori in terms of overall access or the type of pain medicine dispensed. However, Māori patients appeared more likely than non-Māori to first access pain medicines within 2 weeks before their death and commensurately less likely to access them more than 24 weeks before death. CONCLUSION Given the plausibility that there are differences in first access to pain medicines (particularly opioid medicines) among Māori approaching end of life, further investigation of the factors contributing to this disparity is required.

APA, Harvard, Vancouver, ISO, and other styles

2

Motoo, Yoshiharu, and Silke Cameron. "Kampo medicines for supportive care of patients with cancer: A brief review." Integrative Medicine Research 11, no. 2 (June 2022): 100839. http://dx.doi.org/10.1016/j.imr.2022.100839.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Kelly, Kara M. "Complementary and alternative medicines for use in supportive care in pediatric cancer." Supportive Care in Cancer 15, no. 4 (October 12, 2006): 457–60. http://dx.doi.org/10.1007/s00520-006-0162-2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Unguru, Yoram, Melanie Brooke Bernhardt, Stacey L. Berg, Liza-Marie Johnson, Kimberly Pyke-Grimm, Catherine Woodman, and Conrad V. Fernandez. "Chemotherapy and Supportive Care Agents as Essential Medicines for Children With Cancer." JAMA Pediatrics 173, no. 5 (May 1, 2019): 477. http://dx.doi.org/10.1001/jamapediatrics.2019.0070.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Lee, R., and J. Von Roenn. "Is best supportive care really best supportive care?" Journal of Clinical Oncology 27, no. 15_suppl (May 20, 2009): 9639. http://dx.doi.org/10.1200/jco.2009.27.15_suppl.9639.

Full text

Abstract:

9639 Background: With the growth of palliative medicine over the past decade, the paradigm of supportive care has evolved to create new standards for cancer patients. The aim of this study was to define “best supportive care” (BSC) during clinical trials of advanced solid tumors. Methods: Systematic review of the literature using Medline and the Cochrane Central Register of Controlled Trials databases. These were searched for randomized controlled trials in which anticancer therapy was compared with a BSC only arm. Results: A total of 43 studies met our inclusion criteria (publication dates, 1980–2008) with the following cancer types: 22 lung cancer, 6 colorectal, 6 pancreas, 2 gastric, and 7 other cancer types. Thirty-eight studies (88%) provided some definition of supportive care and sixteen studies (37%) used the term BSC. The average survival across treatment arms was 27.5 weeks. All but one study described the use of palliative therapies at the discretion of the treating physician without standardization. Over half of all studies (56%) specifically mentioned analgesics and radiotherapy (RT) for pain control. Other specific interventions listed were steroids (14), antibiotics (10), psychological support (10), nutritional support (9), blood transfusions (8), anti-emetics (6), and anti-depressant or anxiolytic medications (3). One-third of trials (15) reported an equivalent clinical evaluation schedule for both the BSC and treatment arms. Quality of life (QoL) was measured with a validated instrument (e.g., QLQ-30) in 55% of trials and 37% compared the utilization of at least one palliative treatment between groups. Trials using the term BSC were more likely to provide multidisciplinary therapy beyond RT and analgesics (50% vs. 19%; p<0.05). Conclusions: The management of subjects in a BSC arm of clinical trials are highly variable. Overall, the trials compare treatment versus no treatment as subjects in the BSC group likely did not receive care according to current palliative medicine standards. Future randomized clinical trials with a BSC arm should provide a comprehensive, multidisciplinary approach that is consistent with practice guidelines. A standardized BSC approach developed with palliative medicine specialists is warranted for further study. No significant financial relationships to disclose.

APA, Harvard, Vancouver, ISO, and other styles

6

Cassileth, BR, and K. Simon Yeung. "Supportive Cancer Care with Chinese Medicine." Focus on Alternative and Complementary Therapies 15, no. 3 (August 31, 2010): 261–62. http://dx.doi.org/10.1111/j.2042-7166.2010.01039.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Sagar, Stephen M., and Raimond Wong. "Chinese medicine and supportive cancer care." Evidence-Based Integrative Medicine 1, no. 1 (2003): 11–25. http://dx.doi.org/10.2165/01197065-200301010-00005.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Escudero, A., M. Mejia, L. Martínez, C. Martí, G. Marcos, and D. Barreda. "PS-059 Serious medicines errors related to antineoplasic and supportive treatment in cancer patients." European Journal of Hospital Pharmacy 21, Suppl 1 (February 24, 2014): A167.3—A168. http://dx.doi.org/10.1136/ejhpharm-2013-000436.410.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Gourret Baumgart, Jade, Hélène Kane, Sylvie Pelletier, Karine André, Catherine Barbe, Thierry Lecomte, Yacine Sam, Nizar Messai, Emmanuel Rusch, and Frédéric Denis. "Understanding Inequalities in the Uptake of Supportive Care to Improve Practices in the Cancer Care Continuum." Cancers 14, no. 24 (December 8, 2022): 6053. http://dx.doi.org/10.3390/cancers14246053.

Full text

Abstract:

(1) Background: While inequalities in the prevalence of cancer, access to care, and survival have been well documented, less research has focused on inequalities in the uptake of supportive oncology care. Given its contribution to improving the quality of life of people affected by cancer, access to such care is a major public health issue. The present study focuses on the access and uptake of those supportive oncology care services. (2) Methods: This study is based on qualitative research methodology, using a thematic analysis tree on NVivo© analysis software. First, an exploratory survey was conducted with users of oncology services, and professionals from these services and supportive oncology care. Then, individual interviews were conducted in June 2022 among people who are currently being treated or have been treated for cancer. (3) Results: The experiences of the 33 respondents revealed that significant variations in the uptake of supportive oncology care are underpinned by identifiable disparities in their healthcare pathways: in their assimilation of information, difficulties in accessing oncology care, personal reluctance and motivations, perceived needs and benefits, and use of other medicines. (4) Conclusion: This study aims to gain some insight into disparities in the uptake of supportive care in the Centre-Val de Loire region (France). Thus, it provides a better understanding of the complex ways in which these inequalities in supportive oncology care uptake are constructed.

APA, Harvard, Vancouver, ISO, and other styles

10

Sonis, Stephen T. "Genomics, Personalized Medicine, and Supportive Cancer Care." American Society of Clinical Oncology Educational Book, no. 35 (May 2015): 9–16. http://dx.doi.org/10.14694/edbook_am.2015.35.9.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

Shulman, Lawrence N., Claire M. Wagner, Ronald Barr, Gilberto Lopes, Giuseppe Longo, Jane Robertson, Gilles Forte, Julie Torode, and Nicola Magrini. "Proposing Essential Medicines to Treat Cancer: Methodologies, Processes, and Outcomes." Journal of Clinical Oncology 34, no. 1 (January 2016): 69–75. http://dx.doi.org/10.1200/jco.2015.61.8736.

Full text

Abstract:

Purpose A great proportion of the world's cancer burden resides in low- and middle-income countries where cancer care infrastructure is often weak or absent. Although treatment of cancer is multidisciplinary, involving surgery, radiation, systemic therapies, pathology, radiology, and other specialties, selection of medicines that have impact and are affordable has been particularly challenging in resource-constrained settings. In 2014, at the invitation of the WHO, the Union for International Cancer Control convened experts to develop an approach to propose essential cancer medicines to be included in the WHO Model Essential Medicines Lists (EML) for Adults and for Children, as well as a resulting new list of cancer medicines. Methods Experts identified 29 cancer types with potential for maximal treatment impact, on the basis of incidence and benefit of systemic therapies. More than 90 oncology experts from all continents drafted and reviewed disease-based documents outlining epidemiology, diagnostic needs, treatment options, and benefits and toxicities. Results Briefing documents were created for each disease, along with associated standard treatment regimens, resulting in a list of 52 cancer medicines. A comprehensive application was submitted as a revision to the existing cancer medicines on the WHO Model Lists. In May 2015, the WHO announced the addition of 16 medicines to the Adult EML and nine medicines to the Children's EML. Conclusion The list of medications proposed, and the ability to link each recommended medicine to specific diseases, should allow public officials to apply resources most effectively in developing and supporting nascent or growing cancer treatment programs.

APA, Harvard, Vancouver, ISO, and other styles

12

Lo, Shelly S., Lauren Allison Wiebe, Catherine Deamant, Amy Scheu, Betty Roggenkamp, Urjeet Patel, Pam Khosla, et al. "Supportive Oncology Collaborative: Initial impact of supportive oncology screening and care." Journal of Clinical Oncology 34, no. 26_suppl (October 9, 2016): 180. http://dx.doi.org/10.1200/jco.2016.34.26_suppl.180.

Full text

Abstract:

180 Background: The Institute of Medicine (IOM) 2013 report recommends supportive oncology care from diagnosis through survivorship, to end of life. The Coleman Supportive Oncology Collaborative (CSOC) developed a city-wide plan to improve supportive oncology. Metrics derived from the Commission on Cancer (CoC), ASCO Quality Oncology Practice Initiative (ASCO-QOPI) and National Quality Forum (NQF) were used to assess the CSOC impact. Methods: Medical records of consecutive cancer patients from 6 practice improvement cancer centers in Chicago (3 academic, 2 safety-net, 1 public) were reviewed for 2 periods: 2014 (n = 843) and Q1 of 2015 (n = 313). Descriptive statistics assessed differences in quality metrics. Results: Significant improvement was achieved in 6 of 8 core supportive oncology metrics (see table). Conclusions: Consolidated metrics are feasible to assess supportive oncology quality. Early data indicate improvement and effectiveness of the collaborative approach. [Table: see text]

APA, Harvard, Vancouver, ISO, and other styles

13

White, Jeffrey D., Hongsheng Lin, Libin Jia, Roy S. Wu, Stephen Lam, Jie Li, Jinhui Dou, Nagi Kumar, Lizhu Lin, and Lixing Lao. "Proceedings of the Strategy Meeting for the Development of an International Consortium for Chinese Medicine and Cancer." Journal of Global Oncology 3, no. 6 (December 2017): 814–22. http://dx.doi.org/10.1200/jgo.2016.005710.

Full text

Abstract:

On November 3, 2014, in Bethesda, MD, the Office of Cancer Complementary and Alternative Medicine of the National Cancer Institute held a meeting to examine the potential utility and feasibility of establishing an international consortium for Chinese medicine and cancer. There is significant interest in the West in using components of Chinese medicine (CM) —such as botanicals and herbal medicines, acupuncture and acupressure, and qigong—in the field of oncology, as potential anticancer agents, for symptom management, and to improve quality of life. The proposal for a consortium on CM came from the Chinese Academy of Chinese Medical Sciences, with the aims of improving scientific communications and collaborations and modernizing the studies of CM for cancer. The US National Cancer Institute’s Office of Cancer Complementary and Alternative Medicine agreed to work with Chinese Academy of Chinese Medical Sciences to explore the feasibility of establishing an international consortium for Chinese medicine and cancer. At the meeting, participants from the United States, China, Canada, Australia, and Korea discussed issues in CM and cancer research, treatment, and management, including potential mechanisms of action, proof of efficacy, adverse effects, regulatory issues, and the need for improving the quality of randomized clinical trials of CM treatments and supportive care interventions. Presented in these proceedings are some of the main issues and opportunities discussed by workshop participants.

APA, Harvard, Vancouver, ISO, and other styles

14

Védie, Anne-Laure, and Cindy Neuzillet. "Pancreatic cancer: Best supportive care." La Presse Médicale 48, no. 3 (March 2019): e175-e185. http://dx.doi.org/10.1016/j.lpm.2019.02.032.

Full text

APA, Harvard, Vancouver, ISO, and other styles

15

Trosman, Julia Rachel, Christine B. Weldon, Carol A. Rosenberg, James Gerhart, Sofia F. Garcia, William Dale, Urjeet Patel, et al. "Supportive oncology and survivorship care: Initial impact of the Coleman Supportive Oncology Collaborative." Journal of Clinical Oncology 35, no. 5_suppl (February 10, 2017): 2. http://dx.doi.org/10.1200/jco.2017.35.5_suppl.2.

Full text

Abstract:

2 Background: The Institute of Medicine (IOM) and Commission on Cancer (CoC) recommend supportive oncology and survivorship care. The Coleman Supportive Oncology Collaborative (CSOC) aims to improve quality of supportive care and survivorship in Chicago. Methods: CSOC includes 35 institutions (cancer centers, support and hospice), structured in two design teams (Distress & Survivorship and Palliative). Participants identified opportunities and gaps in supportive and survivorship care in an iterative development of: screening tools, follow-up processes, provider training, and quality metrics to assess CSOC impact. Six process improvement sites (2 safety-net, 3 academic & 1 public) reviewed patient charts at baseline and Q1 2015, compared by Fisher’s exact test. Results: Eight metrics contained patient data at the 2 time points; improvements were seen in 6/8 metrics. Conclusions: CSOC successfully developed supportive oncology, survivorship screening, and care processes aligned with IOM and CoC standards. Significant improvements were shown after implementation in diverse settings. Ongoing work will continue to evaluate the impact of the CSOC on patient care. [Table: see text]

APA, Harvard, Vancouver, ISO, and other styles

16

Trosman, Julia Rachel, James Gerhart, Sofia F. Garcia, William Dale, Urjeet Patel, Paramjeet Khosla, Shelly S. Lo, et al. "Supportive oncology and survivorship care: Initial impact of the Coleman Supportive Oncology Collaborative." Journal of Clinical Oncology 35, no. 8_suppl (March 10, 2017): 27. http://dx.doi.org/10.1200/jco.2017.35.8_suppl.27.

Full text

Abstract:

27 Background: The Institute of Medicine (IOM) and Commission on Cancer (CoC) recommend supportive oncology and survivorship care. The Coleman Supportive Oncology Collaborative (CSOC) aims to improve quality of supportive care and survivorship in Chicago. Methods: CSOC includes 35 institutions (cancer centers, support and hospice), structured in two design teams (Distress & Survivorship and Palliative). Participants identified opportunities and gaps in supportive and survivorship care in an iterative development of: screening tools, follow-up processes, provider training, and quality metrics to assess CSOC impact. Six process improvement sites (2 safety-net, 3 academic, and 1 public) reviewed patient charts at baseline and Q1 2015, compared by Fisher’s exact test. Results: Eight metrics contained patient data at the 2 time points; improvements were seen in 6/8 metrics. Conclusions: CSOC successfully developed supportive oncology, survivorship screening, and care processes aligned with IOM and CoC standards. Significant improvements were shown after implementation in diverse settings. Ongoing work will continue to evaluate the impact of the CSOC on patient care.[Table: see text]

APA, Harvard, Vancouver, ISO, and other styles

17

Trosman, Julia Rachel, Betty Roggenkamp, Paramjeet Khosla, Teresa Lillis, Joanna Martin, Mary Pasquinelli, Eileen Knightly, et al. "Multi-institution quality improvement in supportive oncology: Results of the Coleman Supportive Oncology Collaborative (CSOC)." Journal of Clinical Oncology 37, no. 27_suppl (September 20, 2019): 33. http://dx.doi.org/10.1200/jco.2019.37.27_suppl.33.

Full text

Abstract:

33 Background: The Institute of Medicine and Commission on Cancer recommend systematic delivery of supportive oncology care for cancer patients. The CSOC is focused on quality improvement (QI) of supportive care across Chicago cancer centers (Weldon ASCO ’17). Supportive oncology includes distress, practical, family, physical, nutrition, pain, fatigue and care concerns. To support QI, cross-institution teams developed unique, relevant tools, methods, care delivery processes, patient handouts and online training. Methods: Ten centers (5 academic, 1 VA, 1 public, 2 safety net, 1 community) implemented supportive oncology screening and care delivery quality improvements. Centers collected data for relevant Quality Oncology Practice Initiative (QOPI) metrics. Analyses used simple frequencies and Fishers exact test. Results: Five of six QOPI measures were improved at statistically significant levels from 2014 to 2017, p < .00001. Improvements are more modest in 2016 & 2017 as 4 of the centers started this QI in 2017. Conclusions: The CSOC achieved significant improvements in supportive oncology screening and identifying and addressing patients’ needs and concerns. Additional work is needed to improve these measures to achieve the best quality of cancer care possible for every patient based on their needs and concerns. [Table: see text]

APA, Harvard, Vancouver, ISO, and other styles

18

Khosla, Paramjeet, Julia Rachel Trosman, Betty Roggenkamp, Teresa Lillis, Joanna Martin, Shelly S. Lo, Mary Pasquinelli, et al. "Multi-institution quality improvement in supportive oncology: Results of the Coleman Supportive Oncology Collaborative (CSOC)." Journal of Clinical Oncology 37, no. 15_suppl (May 20, 2019): 6606. http://dx.doi.org/10.1200/jco.2019.37.15_suppl.6606.

Full text

Abstract:

6606 Background: The Institute of Medicine and Commission on Cancer recommend systematic delivery of supportive oncology care for cancer patients. The CSOC is focused on quality improvement (QI) of supportive care across Chicago cancer centers (Weldon ASCO ’17). Supportive oncology includes distress, practical, family, physical, nutrition, pain, fatigue and care concerns. To support QI, cross-institution teams developed unique, relevant tools, methods, care delivery processes, patient handouts and online training. Methods: Ten centers (5 academic, 1 VA, 1 public, 2 safety net, 1 community) implemented supportive oncology screening and care delivery quality improvements. Centers collected data for relevant Quality Oncology Practice Initiative (QOPI) metrics. Analyses used simple frequencies and Fishers exact test. Results: Five of six QOPI measures were improved at statistically significant levels from 2014 to 2017, p < .00001. Improvements are more modest in 2016 & 2017 as 4 of the centers started this QI in 2017. Conclusions: The CSOC achieved significant improvements in supportive oncology screening and identifying and addressing patients’ needs and concerns. Additional work is needed to improve these measures to achieve the best quality of cancer care possible for every patient based on their needs and concerns. [Table: see text]

APA, Harvard, Vancouver, ISO, and other styles

19

Weldon, Christine B., James Gerhart, William Dale, Urjeet Patel, Paramjeet Khosla, Shelly S. Lo, Carol Newsom, et al. "Raising all boats in supportive oncology: Initial impact of the Coleman Supportive Oncology Collaborative (CSOC)." Journal of Clinical Oncology 35, no. 15_suppl (May 20, 2017): e18205-e18205. http://dx.doi.org/10.1200/jco.2017.35.15_suppl.e18205.

Full text

Abstract:

e18205 Background: The Institute of Medicine (IOM) and Commission on Cancer (CoC) recommend systematic delivery of supportive oncology and survivorship care to all cancer patients. CSOC aims to improve the quality of supportive care across Chicago-area providers. Methods: 35 CSOC participating institutions (cancer centers, support centers, hospice) formed care delivery design teams Distress, Survivorship & Palliative. Teams collaboratively developed solutions to supportive oncology gaps: patient screening tools, care delivery processes, provider training, and quality metrics to assess supportive oncology quality and the CSOC impact. Six implementation centers (2 safety-net, 3 academic & 1 public) reviewed charts at baseline (2014 diagnoses) and after the initial implementation period (2015 diagnoses), compared by frequencies and Fisher’s exact test. Results: Eight metrics contained patient data at 2 time points; improvements were seen in 7/8 metrics. Conclusions: CSOC developed supportive oncology screening, and care processes aligned with IOM and CoC standards. Significant improvements were shown after implementation across diverse settings. Ongoing work will further evaluate the impact of CSOC efforts on patient care. [Table: see text]

APA, Harvard, Vancouver, ISO, and other styles

20

Gerhart, James, Christine B. Weldon, William Dale, Urjeet Patel, Paramjeet Khosla, Shelly S. Lo, Carol Newsom, et al. "Raising all boats in supportive oncology: Initial impact of the Coleman Supportive Oncology Collaborative (CSOC)." Journal of Clinical Oncology 35, no. 31_suppl (November 1, 2017): 150. http://dx.doi.org/10.1200/jco.2017.35.31_suppl.150.

Full text

Abstract:

150 Background: The Institute of Medicine (IOM) and Commission on Cancer (CoC) recommend systematic delivery of supportive oncology and survivorship care to all cancer patients. CSOC aims to improve the quality of supportive care across Chicago-area providers. Methods: 35 CSOC participating institutions (cancer centers, support centers, hospice) formed care delivery design teams - Distress, Survivorship and Palliative. Teams collaboratively developed solutions to supportive oncology gaps: patient screening tools, care delivery processes, provider training, and quality metrics to assess supportive oncology quality and the CSOC impact. Six implementation centers (2 safety-net, 3 academic & 1 public) reviewed charts at baseline (2014 diagnoses) and after the initial implementation period (2015 diagnoses), compared by frequencies and Fisher’s exact test. Results: Eight metrics contained patient data at 2 time points; improvements were seen in 7/8 metrics. (See Table). Conclusions: CSOC developed supportive oncology screening, and care processes aligned with IOM and CoC standards. Significant improvements were shown after implementation across diverse settings. Ongoing work will further evaluate the impact of CSOC efforts on patient care. [Table: see text]

APA, Harvard, Vancouver, ISO, and other styles

21

Klastersky, Jean. "Supportive care in cancer patients." Lung Cancer 9, no. 1-6 (March 1993): 397–404. http://dx.doi.org/10.1016/0169-5002(93)90697-v.

Full text

APA, Harvard, Vancouver, ISO, and other styles

22

Latter, Sue, Jane B. Hopkinson, Elizabeth Lowson, Jane A. Hughes, Jacki Hughes, Sue Duke, Sally Anstey, et al. "Supporting carers to manage pain medication in cancer patients at the end of life: A feasibility trial." Palliative Medicine 32, no. 1 (July 5, 2017): 246–56. http://dx.doi.org/10.1177/0269216317715197.

Full text

Abstract:

Background: Carers of people with advanced cancer play a significant role in managing pain medication, yet they report insufficient information and support to do so confidently and competently. There is limited research evidence on the best ways for clinicians to help carers with medication management. Aims: To develop a pain medicines management intervention (Cancer Carers Medicines Management) for cancer patients’ carers near the end of life and evaluate feasibility and acceptability to nurses and carers. To test the feasibility of trial research procedures and to inform decisions concerning a full-scale randomised controlled trial. Design: Phase I-II clinical trial. A systematic, evidence-informed participatory method was used to develop CCMM: a nurse-delivered structured conversational process. A two-arm, cluster randomised controlled feasibility trial of Cancer Carers Medicines Management was conducted, with an embedded qualitative study to evaluate participants’ experiences of Cancer Carers Medicines Management and trial procedures. Setting: Community settings in two study sites. Participants: Phase I comprises 57 carers, patients and healthcare professionals and Phase II comprises 12 nurses and 15 carers. Results: A novel intervention was developed. Nurses were recruited and randomised. Carer recruitment to the trial was problematic with fewer than predicted eligible participants, and nurses judged a high proportion unsuitable to recruit into the study. Attrition rates following recruitment were typical for the study population. Cancer Carers Medicines Management was acceptable to carers and nurses who took part, and some benefits were identified. Conclusion: Cancer Carers Medicines Management is a robustly developed medicines management intervention which merits further research to test its effectiveness to improve carers’ management of pain medicines with patients at the end of life. The study highlighted aspects of trial design that need to be considered in future research.

APA, Harvard, Vancouver, ISO, and other styles

23

Wei, Min. "Identification of pharmacogenetic markers in cancer supportive care." Journal of Clinical Oncology 36, no. 34_suppl (December 1, 2018): 109. http://dx.doi.org/10.1200/jco.2018.36.34_suppl.109.

Full text

Abstract:

109 Background: Precision medicine has become increasingly critical in cancer supportive care, with implications for treatment selection, medication dosing, and side effect prediction. The presence of clinically actionable germline variants brought the hope that accurate prediction of drug efficacy and toxicity would be in the future. This will greatly improve the comprehensive oncology care, where supportive care treatment options can be subjective and personalized. Methods: The changes in drug effect and toxicity caused by genetic variations were characterized in 4,287 patients submitted for clinical pharmacogenetics testing using a gene panel including key pharmacokinetic and pharmacodynamic genes. For each patient, the need to select an alternate medication and adjust medication dose was determined for the treatment of pain (CYP2D6, CYP1A2, OPRM1), nausea/vomiting (CYP2D6), antifungal prophylaxis (CYP2C19), and depression (CYP2D6, CYP2C19). It is recognized that there are many other factors playing in the variations of the response and toxicity to these classes of medications. Results: Of the 4,287 patients, 964 (22%) would have a recommendation to choose alternatives of oxycodone, codeine, or tramadol therapy and 3,394 patients (79%) for a non-standard dosage. A change in certain antiemetics such as ondansetron would be suggested for 171 patients (4%). If voriconazole antifungal prophylaxis was clinical required, 1,228 (29%) would need a dose increase, while 133 (3%) should be switched to a different regimen. 2,727 patients (64%) should avoid or adjust dosage on some of the commonly used agents for depression due to reduced efficacy or heightened risk of toxicity. Conclusions: Pharmacogenetics markers associated with reduced drug efficacy and higher rate of ADRs were commonly observed for medications used in cancer supportive care. Identification of these markers would help clinicians achieve optimal treatment outcome with manageable time and cost. This provides great opportunities to apply precision medicine principles to patient management.

APA, Harvard, Vancouver, ISO, and other styles

24

Zaid, Hilal, Michael Silbermann, Eran Ben-Arye, and Bashar Saad. "Greco-Arab and Islamic Herbal-Derived Anticancer Modalities: From Tradition to Molecular Mechanisms." Evidence-Based Complementary and Alternative Medicine 2012 (2012): 1–13. http://dx.doi.org/10.1155/2012/349040.

Full text

Abstract:

The incidence of cancer is increasing in the developed countries and even more so in developing countries parallel to the increase in life expectancy. In recent years, clinicians and researchers advocate the need to include supportive and palliative care since the establishment of the diagnosis and throughout the duration of treatment, with the goal of improving patients' quality of life. This patient-centered approach in supportive care is also shared by various traditional and complementary medicine approaches. Traditional Arab-Islamic medicine offers a variety of therapeutic modalities that include herbal, nutritional, and spiritual approaches. Physicians and scholars, such as Avicenna (980–1037), Rhazes (965–915), Al Zahrawi (936–1013), and Ibn al Nafis (1218–1288) referred to cancer etiology in various medicinal texts and suggested both preventive and therapeutic remedies to alleviate suffering. This review presents research data related to the anticancer activities of herbs used in Arab-Islamic medicine and allude to their potential role in improving the quality of life of cancer patients.

APA, Harvard, Vancouver, ISO, and other styles

25

Woodman, R. "NHS cancer patients denied supportive treatments." BMJ 319, no. 7224 (December 11, 1999): 1520. http://dx.doi.org/10.1136/bmj.319.7224.1520.

Full text

APA, Harvard, Vancouver, ISO, and other styles

26

Pohl, Gudrun M. I., and Heinz Ludwig. "Supportive treatment for anemic cancer patients." Wiener Medizinische Wochenschrift 154, no. 9-10 (May 2004): 226–34. http://dx.doi.org/10.1007/s10354-004-0070-3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

Fincham, Lorraine, Gina Copp, Kay Caldwell, Louise Jones, and Adrian Tookman. "Supportive care: experiences of cancer patients." European Journal of Oncology Nursing 9, no. 3 (September 2005): 258–68. http://dx.doi.org/10.1016/j.ejon.2004.08.004.

Full text

APA, Harvard, Vancouver, ISO, and other styles

28

Shalom-Sharabi, Ilanit, Moshe Frenkel, Opher Caspi, Gil Bar-Sela, Martine Toledano, Noah Samuels, Elad Schiff, and Eran Ben-Arye. "Integrative Oncology in Supportive Cancer Care in Israel." Integrative Cancer Therapies 17, no. 3 (April 2, 2018): 697–706. http://dx.doi.org/10.1177/1534735418764839.

Full text

Abstract:

Purpose: Integrative oncology (IO) services provide complementary/integrative medicine (CIM) therapies to patients as part of their supportive cancer care. In this study, we examine and compare the structural, operational, financial and academic/research-related aspects of IO services in Israeli oncology centers. Methods: The medical directors of seven Israeli IO programs completed questionnaires which explored the objectives and organizational features of their service within the context of supportive cancer care. Results: All participating IO services addressed patient-reported concerns related to quality of life and function, within the context of conventional supportive cancer care. The centers shared similar characteristics regarding the procedure of referral to their service and emphasized research and teaching initiatives within an academic framework, as part of their clinical practice. A number of obstacles to integration were identified, primarily those related to financial considerations, such as the need for patients to carry the cost of the CIM treatments. Conclusions: IO services situated within conventional oncology departments in Israel share a number of characteristics, as well as obstacles to their incorporation into standard care. All participating centers described both clinical and academic activities, including research initiatives and the promotion of CIM in an academic setting. Further research is needed in order to better understand the place of CIM in the oncology setting and prioritize the allocation of resources in order to advance the inclusion of CIM in standard supportive cancer care.

APA, Harvard, Vancouver, ISO, and other styles

29

De Cicco, Marcello, Roberto Bortolussi, Dario Fantin, Mira Matovic, Augusto Fracasso, Fabio Fabiani, and Cristina Santantonio. "Supportive therapy of elderly cancer patients." Critical Reviews in Oncology/Hematology 42, no. 2 (May 2002): 189–211. http://dx.doi.org/10.1016/s1040-8428(01)00162-7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

30

Matsuda, Yoshinobu, Takashi Yamaguchi, Yoshihisa Matsumoto, Hiroto Ishiki, Yuko Usui, Jun Kako, Kozue Suzuki, et al. "Research policy in supportive care and palliative care for cancer dyspnea." Japanese Journal of Clinical Oncology 52, no. 3 (December 11, 2021): 260–65. http://dx.doi.org/10.1093/jjco/hyab193.

Full text

Abstract:

Abstract Background Dyspnea is a common and distressing symptom in patients with cancer. To improve its management, multicenter confirmatory studies are necessary. Research policy would be useful in conducting these studies. Here, we propose a new research policy for the management of dyspnea in patients with cancer. Methods The first draft was developed by a policy working group of 11 specialists in the field of supportive care or palliative care for dyspnea. Then, a provisional draft was developed after review by a research support group (the Japanese Supportive, Palliative and Psychosocial Care Study Group) and five Japanese scientific societies (Japanese Association of Supportive Care in Cancer, Japanese Society of Medical Oncology, Japanese Society of Palliative Medicine, Japanese Association of Rehabilitation Medicine and Japanese Society of Clinical Oncology), and receipt of public comments. Results The policy includes the following components of research policy on dyspnea: (i) definition of dyspnea, (ii) scale for assessment of dyspnea, (iii) reason for dyspnea or factors associated with dyspnea and (iv) treatment effectiveness outcomes/adverse events. The final policy (Ver1.0) was completed on 1 March 2021. Conclusions This policy could help researchers plan and conduct studies on the management of cancer dyspnea.

APA, Harvard, Vancouver, ISO, and other styles

31

Hess, Suzanne M., and Lynda M. Beaupin. "Growing Healing Touch as supportive cancer care in western New York." Journal of Clinical Oncology 35, no. 5_suppl (February 10, 2017): 176. http://dx.doi.org/10.1200/jco.2017.35.5_suppl.176.

Full text

Abstract:

176 Background: Healing Touch (HT) is a specific energy medicine modality that incorporates several techniques to balance the human energy field to help promote healing. It is a safe and non-invasive therapy that complements traditional, standard care and is recognized by NIH’s National Center for Complementary and Integrative Health. HT was first introduced to cancer survivors at our NCI-designated Comprehensive Cancer Center in 2013. We demonstrate HT is well-received and easy to integrate into traditional cancer care. Methods: A Certified Healing Touch Practitioner taught pediatric survivors and families HT techniques, as well as trained staff and volunteers to participate in the pilot program and to offer HT sessions throughout the year. Results: See Table. Qualitative analysis of participant’s feedback indicate benefits in the following themes: 1. Physical Symptom Relief 2. Emotional Issue Relief 3. Spiritual/Grief Support 4. Recommendation to Other Patients. Conclusions: Healing Touch is an energy medicine modality that is easy to teach, simple to integrate into routine cancer care, and beneficial for caregivers and survivors alike. [Table: see text]

APA, Harvard, Vancouver, ISO, and other styles

32

Boateng, Rhonda, Lorna Renner, Kadia Petricca, Sumit Gupta, and Avram Denburg. "Health system determinants of access to essential medicines for children with cancer in Ghana." BMJ Global Health 5, no. 9 (September 2020): e002906. http://dx.doi.org/10.1136/bmjgh-2020-002906.

Full text

Abstract:

BackgroundEvidence of the context-specific challenges related to childhood cancer drug (CCD) access is vital to improving outcomes for children with cancer in low- and middle-income countries, such as Ghana. We sought to determine the availability and cost of essential CCD in Ghana and identify the underlying determinants of access.MethodsOur study integrated quantitative data on drug prices and availability with qualitative insights into health system and sociopolitical determinants of CCD access in Ghana. We analysed retrospective monthly price and stock data for 41 cancer and supportive care drugs on the WHO Essential Medicines List (EML) from private retail and public institutional pharmacies. Non-parametric analyses evaluated relationships between drug price and availability, and impacts of drug class and formulation on availability and procurement efficiency. We assessed the determinants of drug access through thematic analysis of policy documents and semi-structured interviews (n=21) with key health system stakeholders.ResultsGhana lists only 47% of essential CCD on its National EML, revealing gaps in domestic formulary inclusion. Stock-outs occurred for 88% of essential CCD, with a 70-day median stock-out duration; 32% had median price ratios above internationally-accepted efficiency thresholds. Drugs procured inefficiently were more susceptible to stock-outs (p=0.0003). Principal determinants of drug access included: (1) lack of sociopolitical priority afforded childhood cancer and (2) the impact of policy and regulatory environments on drug affordability, availability and quality. Establishment of a population-based cancer registry, a nationally-coordinated procurement strategy for CCD, public financing for childhood cancer care and policies to control drug costs emerged as priority interventions to improve drug access in Ghana.ConclusionOur study provides context-specific evidence to enable responsive policy development for efficient drug procurement and supply management in Ghana and establishes a rigorous approach to the analysis of childhood cancer drug access in similar health system settings.

APA, Harvard, Vancouver, ISO, and other styles

33

Reichek, Jennifer, Christine B. Weldon, Rani Ganesan, Eugene Suh, Dipti Dighe, Julia Rachel Trosman, Daniel K. Choi, et al. "Areas for quality improvement in pediatric supportive oncology services." Journal of Clinical Oncology 35, no. 15_suppl (May 20, 2017): e22022-e22022. http://dx.doi.org/10.1200/jco.2017.35.15_suppl.e22022.

Full text

Abstract:

e22022 Background: In 2013, the Institute of Medicine report recommended that supportive oncology services be initiated at time of diagnosis. Providers of pediatric cancer care in the Chicagoland community, supported by The Coleman Foundation, sought to define areas for quality improvement of supportive oncology delivery to children. Methods: Focus groups and surveys with clinicians providing pediatric cancer care and supportive services at 14 sites were used to prioritize areas needing improvement. Results: 100% (14/14) of sites participated. Of the eligible sites, 6 were pediatric cancer treatment sites and 8 cancer care community organizations. Sites demonstrated consistent agreement for 8 of the 12 areas of focus for improvement. Over 50% of sites reported areas of focus (table) as important or very important. Conclusions: Sites identified the need for quality improvement in delivery of psychosocial, survivorship and palliative care for pediatric cancer patients. Survey results demonstrate a need for collaboration and efforts to guide care delivery improvement across sites. [Table: see text]

APA, Harvard, Vancouver, ISO, and other styles

34

Reichek, Jennifer, Christine B. Weldon, Eugene Suh, Julia Rachel Trosman, Stacy D. Sanford, Dipti Dighe, Rosa Berardi, et al. "Areas for quality improvement in pediatric supportive oncology services." Journal of Clinical Oncology 35, no. 31_suppl (November 1, 2017): 146. http://dx.doi.org/10.1200/jco.2017.35.31_suppl.146.

Full text

Abstract:

146 Background: In 2013, the Institute of Medicine report recommended that supportive oncology services be initiated at time of diagnosis. Providers of pediatric cancer care in the Chicagoland community, supported by The Coleman Foundation, sought to define areas for quality improvement of supportive oncology delivery to children. Methods: Focus groups and surveys with clinicians providing pediatric cancer care and supportive services at 14 sites were used to prioritize areas needing improvement. Results: 100% (14/14) of sites participated. Of the eligible sites, 6 were pediatric cancer treatment sites and 8 cancer care community organizations. Sites demonstrated consistent agreement for 8 of the 12 areas of focus for improvement. Over 50% of sites reported areas of focus (table) as important or very important. Conclusions: Sites identified the need for quality improvement in delivery of psychosocial, survivorship and palliative care for pediatric cancer patients. Survey results demonstrate a need for collaboration and efforts to guide care delivery improvement across sites. [Table: see text]

APA, Harvard, Vancouver, ISO, and other styles

35

Yamakawa, Jun-ichi, Yoshiharu Motoo, Junji Moriya, Masao Ogawa, Hiroaki Uenishi, Sumiyo Akazawa, Toshiyuki Sasagawa, Matomo Nishio, and Junji Kobayashi. "Significance of Kampo, Traditional Japanese Medicine, in Supportive Care of Cancer Patients." Evidence-Based Complementary and Alternative Medicine 2013 (2013): 1–10. http://dx.doi.org/10.1155/2013/746486.

Full text

Abstract:

The current standard treatment for cancer is a multidisciplinary therapy whereby various types of treatment are properly combined. Chemotherapy with multiple anticancer drugs is now common, and traditional, complementary, and alternative therapies are adopted as supportive measures. Medical care in Japan is distinguished by the ability for patients to access both Western and Kampo medical cares at the same time. There is a high degree of trust in the safety of Kampo therapies because they are practiced by medical doctors who are educated with fundamental diagnosis of Western medicine. Highly reliable clinical studies are being published, demonstrating that palliative or supportive care for cancer patients using Kampo preparations alleviates adverse effects of chemotherapy or radiotherapy. This paper reports the circumstances around cancer care in Japan where traditional therapeutic Kampo formulas are used for patients undergoing cancer treatment with cutting-edge chemotherapy, specifically to alleviate adverse effects of anticancer drugs.

APA, Harvard, Vancouver, ISO, and other styles

36

Lin, Jaung-Geng, and Yi-Hung Chen. "The Role of Acupuncture in Cancer Supportive Care." American Journal of Chinese Medicine 40, no. 02 (January 2012): 219–29. http://dx.doi.org/10.1142/s0192415x12500176.

Full text

Abstract:

Acupuncture has many beneficial effects during cancer therapy and has proven efficacy in the management of side effects induced by chemotherapy and radiotherapy. In this review, we discussed the benefits of acupuncture on cancer patients. In cancer pain management, acupuncture is effective for head and neck pain, waist pain, abdominal and chest pain. Many studies confirm the excellent efficacy of acupuncture against symptoms of vomiting and nausea, including those induced by chemotherapy and radiotherapy. Head and neck cancer patients receiving radiotherapy may develop xerostomia, which may be relieved by acupuncture. Acupuncture may also cause sedative and hypnotic effects in cancer patients for treating nervousness and insomnia.

APA, Harvard, Vancouver, ISO, and other styles

37

Berman, Richard, Elizabeth Elliott, Lisa LaMola, Carole Mula, Hannah Talbot, Sacha Kong, Wendy Makin, and Julian Scott-Warren. "O-1 Enhanced supportive care in cancer." BMJ Supportive & Palliative Care 7, Suppl 1 (March 2017): A1.1—A1. http://dx.doi.org/10.1136/bmjspcare-2017-00133.1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

Balboni, Tracy A., Ka-Kit P. Hui, and Arif H. Kamal. "Supportive Care in Lung Cancer: Improving Value in the Era of Modern Therapies." American Society of Clinical Oncology Educational Book, no. 38 (May 2018): 716–25. http://dx.doi.org/10.1200/edbk_201369.

Full text

Abstract:

Driven by a discipline-wide imperative to maximize patient centeredness and value, supportive care services have experienced remarkable growth and acceptance in oncology care. Two such services with a growing evidence base and examples of routine integration into usual oncology care are palliative care and integrative medicine. Both focus on the patient experience with cancer during and after cancer-directed treatments occur, from diagnosis through survivorship or end-of-life care. With a frame of increasing value for all in the oncology care ecosystem, we highlight the evidence for how these two disciplines can improve the experience of patients with cancer and their loved ones. We further highlight how additional focus in palliative care and integrative medicine can continue to build toward a shared vision of high-value, high-quality cancer care.

APA, Harvard, Vancouver, ISO, and other styles

39

Frazer, Morgan B., Joseph Bubalo, Himanshu Patel, Jim Siderov, Milagros Cubilla, Mário De Lemos, Harbans Dhillon, et al. "International Society of Oncology Pharmacy Practitioners global position on the use of biosimilars in cancer treatment and supportive care." Journal of Oncology Pharmacy Practice 26, no. 3_suppl (April 2020): 3–10. http://dx.doi.org/10.1177/1078155219893441.

Full text

Abstract:

With the development of innovative cancer treatments over recent decades, the cost of cancer care has risen exponentially, limiting patient access to patented originator biotherapeutics in many countries. The introduction of biosimilars to the market has created new opportunities as well the need for changes in practice within healthcare institutions. A ‘biosimilar’ is a biotherapeutic product which is highly similar in terms of quality, safety and efficacy to an already licensed originator product. Although biosimilars lack clinically meaningful differences in therapeutic activity as compared to the originator product, these complex biological molecules are not considered identical chemical copies, unlike generics, and minor differences in molecular structure and inactive compounds may exist. A thorough understanding of these differences and their clinical implications is necessary for optimising medicines-use practices involving biosimilars. This position statement, developed by the International Society of Oncology Pharmacy Practitioners Biosimilars Taskforce, aims to provide the global oncology pharmacy community with guidance to support decisions around biosimilar use. The 11 statements cover the regulation and evaluation of biosimilars, practical issues around local implementation, the education of healthcare staff and patients, and the requirement for ongoing pharmacovigilance and outcome monitoring.

APA, Harvard, Vancouver, ISO, and other styles

40

Trosman, Julia Rachel, Rosa Berardi, and Christine B. Weldon. "What is needed to implement Institute of Medicine (IOM) 2013 supportive oncology recommendations in community settings?" Journal of Clinical Oncology 34, no. 7_suppl (March 1, 2016): 49. http://dx.doi.org/10.1200/jco.2016.34.7_suppl.49.

Full text

Abstract:

49 Background: The IOM 2013 report recommends supportive oncology services from diagnosis through survivorship and end of life. We examined what community institutions need to implement IOM recommendations. Methods: Survey of 35 institutions in a urban area (13 cancer centers; 14 cancer support centers, 8 hospices). Institutions ranked the top 5 supportive oncology project ideas, that their organization was most interested in participating in, from a list of 27. Results: Survey response rate was 100%. Respondents agreed on 8 of top 10 priorities across the three organization types (Table). Local inter-institutional collaboration leveraging respective resources and facilitating care consistency across sites was the most frequently need. It was followed by the need for stratified care processes based on patient need and improved supportive oncology reimbursement. Priorities differed between Cancer Centers and other institution types on Consolidated screening tools* (p = .05, .09) and Care process for family / caregiver** (p = .006, .04). Conclusions: Supportive oncology care processes and tools are needed to implement IOM recommendations in the community. Our findings inform a roadmap for practical collaborative implementation of the IOM recommendations. Differing priorities across cancer institution types should be further explored and addressed within the roadmap. [Table: see text]

APA, Harvard, Vancouver, ISO, and other styles

41

Rajendran, E. S. "Homeopathy as a supportive therapy in cancer." Homeopathy 93, no. 2 (April 2004): 99–102. http://dx.doi.org/10.1016/j.homp.2004.02.008.

Full text

APA, Harvard, Vancouver, ISO, and other styles

42

Singh, Lalit Raj, and Sunita Garg. "Medicinal Potential of Laxmi Taru (Simarouba Glauca DC)." Dev Sanskriti Interdisciplinary International Journal 18 (July 31, 2021): 40–45. http://dx.doi.org/10.36018/dsiij.v18i.220.

Full text

Abstract:

Cancer is becoming a high-profile disease throughout the world and for its treatment most prevalent technique is chemotherapy which has its limitations due to many toxic or side effects on healthy or non-cancerous body parts. Therefore, there is a demand for alternative and supportive anticancer agents for treatments which are naturally-derived with minimal side effects. This review paper highlights the therapeutic importance, safety, and efficacy of the Laxmi Taru along with their active constituents used either as single plant-decoctions, extracts, or in combinations especially in some traditional herbal medicines. World Health organization (WHO) is promoting this concept as ‘Save plants to save lives.’ Among the key health issues, WHO have also said that, cancer is the second leading cause of death globally. The plethora of secondary metabolites (therapeutic agents) found in the plant are the rich source to find the alternative safe anti-cancer agents.

APA, Harvard, Vancouver, ISO, and other styles

43

Zenda, Sadamoto, Yosuke Uchitomi, Tatsuya Morita, Takuhiro Yamaguchi, and Akira Inoue. "Establishment of a research policy for supportive and palliative care in Japan." Japanese Journal of Clinical Oncology 51, no. 4 (February 10, 2021): 538–43. http://dx.doi.org/10.1093/jjco/hyab008.

Full text

Abstract:

Abstract Background While several small groups in Japan have attempted to conduct prospective studies in the field of supportive and palliative care, development of exploratory research into multicentre confirmatory studies has been difficult. The main reason for this is the difference in clinical research methodology in supportive and palliative care compared with medical oncology in terms of the style of multidisciplinary approaches, study design and endpoints. Here, we establish a new research policy for cancer supportive and palliative care in Japan. Methods The first draft was developed by a policy working group within the Japanese Supportive, Palliative and Psychosocial Care Study Group. A provisional draft was subsequently developed after review by nine Japanese scientific societies (Japanese Association of Supportive Care in Cancer, Japanese Society of Medical Oncology, Japanese Society of Clinical Oncology, Japanese Society of Palliative Medicine, Japanese Society of Cancer Nursing, Japanese Society of Pharmaceutical Oncology (JASPO), Japan Cancer Association (JCA), Japanese Society of Therapeutic Radiation Oncology and Japanese Cancer Association) and receipt of public comments. The final research policy in the area of supportive and palliative care in Japan (Ver1.0) was completed in December 2018 and underwent its first revision (Ver1.1) in February, 2020. Results The policy includes the following components of clinical research: (i) objective of the research policy in the areas of supportive and palliative care; (ii) definitions of supportive care and palliative care; (iii) characteristics of supportive and palliative care research; (iv) target population for research; (v) research design; (vi) endpoints and assessment measures; (vii) handling of the deaths of subjects and (viii) operational structure and quality management. Conclusions We hope that studies conducted according to this policy will play important roles in the future development of the supportive and palliative field.

APA, Harvard, Vancouver, ISO, and other styles

44

Trosman, Julia Rachel, James Gerhart, Urjeet Patel, Paramjeet Khosla, Patricia A. Robinson, Frank J. Penedo, Aidnag Diaz, et al. "Results of implementing a novel supportive oncology screening tool for comprehensive evaluation of distress and other supportive care needs." Journal of Clinical Oncology 35, no. 15_suppl (May 20, 2017): e21644-e21644. http://dx.doi.org/10.1200/jco.2017.35.15_suppl.e21644.

Full text

Abstract:

e21644 Background: The Institute of Medicine (IOM) 2013 Report recommends that supportive oncology care start at cancer diagnosis; the Commission on Cancer (CoC) Standard 3.2 requires distress screening and indicated action. Screening tools are not standardized and often address only a portion of patients’ supportive oncology needs. Methods: A collaborative of 100+ clinicians, funded by The Coleman Foundation, developed a patient-centric screening tool adapted from NCCN Distress Problem List, IOM report and CoC standards, with validated sub-tools: PHQ-4 for anxiety and depression and PROMIS short forms for pain, fatigue and physical function. Novel treatment/care and other concerns were included. The screening tool was implemented at 4 cancer centers (2 academic, 1 public & 1 safety-net). End points included correlation of PHQ-4 score with other supportive oncology needs. Descriptive statistics, Fisher’s exact test were used. Results: 2805 patients were screened. Average scores were: PHQ4 – Anxiety and Depression 1.8 (mild > 3), Pain 4.5 (mild > 4), Fatigue 8.8 (mild > 6), Physical Function 20.2 (mild < 20), see table for additional items. Higher scores on the PHQ-4 were significantly associated with each of the following: greater pain, fatigue, nutritional and specific treatment/care concerns, and lower physical function (p<.0001). Conclusions: Patients with higher anxiety and depression also have many other supportive oncology concerns. Our results support the use of a comprehensive tool capturing a spectrum of each patient’s unique concerns. This may enable earlier interventions and personalized delivery of supportive care. [Table: see text]

APA, Harvard, Vancouver, ISO, and other styles

45

Khosla, Paramjeet, Julia Rachel Trosman, James Gerhart, Urjeet Patel, Shelly S. Lo, Frank J. Penedo, Patricia A. Robinson, et al. "Results of implementing a novel supportive oncology screening tool for comprehensive evaluation of distress and other supportive care needs." Journal of Clinical Oncology 35, no. 31_suppl (November 1, 2017): 61. http://dx.doi.org/10.1200/jco.2017.35.31_suppl.61.

Full text

Abstract:

61 Background: The Institute of Medicine (IOM) 2013 Report recommends that supportive oncology care start at cancer diagnosis; the Commission on Cancer (CoC) Standard 3.2 requires distress screening and indicated action. Screening tools are not standardized and often address only a portion of patients’ supportive oncology needs. Methods: A collaborative of 100+ clinicians, funded by The Coleman Foundation, developed a patient-centric screening tool adapted from NCCN Distress Problem List, IOM report and CoC standards, with validated sub-tools: PHQ-4 for anxiety and depression and PROMIS short forms for pain, fatigue and physical function. Novel treatment/care and other concerns were included. The screening tool was implemented at 4 cancer centers (2 academic, 1 public & 1 safety-net). End points included correlation of PHQ-4 score with other supportive oncology needs. Descriptive statistics, Fisher’s exact test were used. Results: 2805 patients were screened. Average scores were: PHQ4 – Anxiety and Depression 1.8 (mild > 3), Pain 4.5 (mild > 4), Fatigue 8.8 (mild > 6), Physical Function 20.2 (mild < 20), see table for additional items. Higher scores on the PHQ-4 were significantly associated with each of the following: greater pain, fatigue, , nutritional and specific treatment/care concerns, and lower physical function (p<.0001). (See Table). Conclusions: Patients with higher anxiety and depression also have many other supportive oncology concerns. Our results support the use of a comprehensive tool capturing a spectrum of each patient’s unique concerns. This may enable earlier interventions and personalized delivery of supportive care. [Table: see text]

APA, Harvard, Vancouver, ISO, and other styles

46

Balducci, Lodovico, and Ignazio Carreca. "Supportive care of the older cancer patient." Critical Reviews in Oncology/Hematology 48 (October 2003): S65—S70. http://dx.doi.org/10.1016/j.critrevonc.2003.06.001.

Full text

APA, Harvard, Vancouver, ISO, and other styles

47

Mahillo, B. Astibia, K. Velázquez Kennedy, A. Jiménez Martín, M. C. Tenorio Núñez, A. Vallés Carboneras, L. Pérez Lamas, C. Jiménez Chillón, F. J. López Jiménez, and G. Moreno Jiménez. "Topic: AS08-Treatment/AS08k-Supportive care - Transfusion medicine and MDS." Leukemia Research 108 (September 2021): 106681.61. http://dx.doi.org/10.1016/j.leukres.2021.106681.61.

Full text

APA, Harvard, Vancouver, ISO, and other styles

48

Yocavitch, Liana, Gregory D. Garber, Alison Petok, Brooke Worster, and Nathan Handley. "Development of a multidisciplinary approach to supportive care for patients with genitourinary cancers." Journal of Clinical Oncology 37, no. 27_suppl (September 20, 2019): 88. http://dx.doi.org/10.1200/jco.2019.37.27_suppl.88.

Full text

Abstract:

88 Background: Patients with cancer who engage early with palliative care may experience improved quality of life (QOL), increased overall survival (OS), and decreased acute care utilization. The Neu Center for Supportive Medicine and Cancer Survivorship (NCSMC) at Thomas Jefferson University is a program designed to identify patients who would benefit from early intervention palliative and supportive care and deliver appropriate services. After initial experience with the model in patients with gastrointestinal and head and neck malignancies, the NCSMC is expanding to patients with genitourinary cancers. Methods: A multidisciplinary team consisting of palliative care physicians, social work, psychology, and navigation conducts biopsychosocial screening (using the NCCN Distress Thermometer) and initiates a personalized care plan for each patient to clarify treatment goals and offer assistance. Prior to deploying the program, multiple stakeholders were engaged to discuss optimal screening points in the patient journey. Patients with a new cancer diagnosis are approached at a post-operative visit in the urology clinic; patients with high distress or significant barriers are discussed at a weekly interdisciplinary meeting with a team of physicians, nurses, social workers, and psychiatry. Patients are subsequently referred to services identified as potentially beneficial. Results: In the first 10 weeks of the program, 67 patients with new diagnoses of bladder (28, 41.8%), prostate (21, 31.3%), kidney (12, 17.9%), urothelial (5, 7.5%), and testicular (1, 1.5%) cancers were screened. 38 (59.4%) patients were identified as low distress; 24 patients (36%) were identified as high distress and offered NCSMC services. Two patients utilized services. Conclusions: Distress and barriers to care amongst patients with newly diagnosed genitourinary cancers are highly variable. While evaluating all patients in the immediate post-operative period is effective at identifying affected patients, the process is resource intensive. An iterative approach testing the intervention at different points in the patient journey is ongoing. As the program matures, impact on QOL, OS, and utilization will be measured.

APA, Harvard, Vancouver, ISO, and other styles

49

Lam, Wai Ching, Linda Zhong, Yuqi Liu, Nannan Shi, Bacon Ng, Eric Ziea, Zhaoxiang Bian, and Aiping Lu. "Hong Kong Chinese Medicine Clinical Practice Guideline for Cancer Palliative Care: Pain, Constipation, and Insomnia." Evidence-Based Complementary and Alternative Medicine 2019 (January 22, 2019): 1–13. http://dx.doi.org/10.1155/2019/1038206.

Full text

Abstract:

It is common for patients with cancers in Hong Kong seeking Chinese Medicine (CM) therapies as supportive care during cancer treatment and to manage treatment-related side effects. This article provides clinical practice guideline (CPG) on the use of CM for specific clinical indications caused by cancer and during cancer treatment, including pain, constipation, and insomnia, and aims to guide local licensed CM practitioners and provide beneficial reference for social medical decision makers and patients. In this manuscript, we summarize the clinical manifestation, CM pattern classification, and CM intervention including herbal treatment, acupuncture treatment, regulating, and nursing based on pattern differentiation.

APA, Harvard, Vancouver, ISO, and other styles

50

Mohammad I M, Hojouj. "Using Telemedicine for Providing Supportive and Palliative Care Patients with Advanced Cancer during the COVID?19 Pandemic in Ukraine." Biomedical Research and Clinical Reviews 3, no. 5 (April 19, 2021): 01–03. http://dx.doi.org/10.31579/2692-9406/053.

Full text

Abstract:

COVID‐19 has overwhelmed the capacity of health care systems, limiting access to supportive and palliative care for patients with advanced cancer. Telemedicine has emerged as a tool to provide care continuity to patients while limiting the risk of contagion. However, implementing telemedicine in resource‐limited settings is challenging. We report the results of a multidisciplinary patient‐navigator‐led telemedicine supportive care program in Dnipro City. One‐hundred sixty‐five telemedicine interventions were provided to 50 patients (median age 67, 47% female). A quarter of the patients had less than or equal to elementary school education, and 18% lived in a rural area. The most common interventions were psychological care (30%), pain and symptom control (27%), and nutritional counseling (10%). Half of the interventions were provided by video conferencing. The most common patient‐reported barrier was limited experience using communication technology. Our results demonstrate the feasibility of providing supportive and palliative care interventions using telemedicine in resource‐limited settings.

APA, Harvard, Vancouver, ISO, and other styles

Journal articles on the topic 'Supportive medicines in cancer'

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles